GenePoweRx has joined hands with MGI Tech in a strategic partnership to deliver AI-powered genomic solutions for predictive healthcare and personalized medicine. The collaboration aims to enhance global access to rapid, accurate, and preventive genomic insights.

Hyderabad: GenePoweRx, a leading innovator in AI-driven personalized medicine, has announced a strategic co-marketing partnership with MGI Tech Co., Ltd., a global player in life sciences technology. The collaboration is set to transform the future of predictive healthcare, precision medicine, and longevity science by integrating cutting-edge genomic sequencing with artificial intelligence-based analytics.

The two companies aim to leverage their strengths—MGI’s robust sequencing platforms and GenePoweRx’s advanced bioinformatics and AI engine—to deliver fast, accurate, and clinical-grade genomic solutions for both individuals and institutions worldwide.

A game-changer in preventive healthcare

“This collaboration with MGI is a game-changer for personalized medicine,” said Dr. Kalyan Ram Uppaluri, Founder of GenePoweRx. “By combining MGI’s sequencing capabilities with our AI-powered interpretation tools, we are set to redefine accuracy and turnaround times in the space of genomic diagnostics.”

Echoing the sentiment, Dr. Hima Jyothi Challa, MD at GenePoweRx, added, “We aim to make personalized and preventive healthcare not just available, but actionable for everyone.”

Roy Tan, General Manager of MGI Asia Pacific, said, “Through this collaboration, we hope to strengthen GenePoweRx’s capabilities and empower both healthcare providers and patients with transformative health insights.”

He added that the partnership represents a major leap toward democratizing access to advanced healthcare technologies by embedding precision genomics into everyday medical decision-making.